LincoMed® 100
lincomycin injection, USP
Swine Antibiotic
Restricted Drug (California) - Use only as Directed.
ANADA 200-368, Approved by FDA®
Net Contents: 100 mL (3.3 fl oz)
LincoMed® 100 contains lincomycin hydrochloride, an antibiotic produced by Streptomyces lincolnensis var. lincolnensis which is chemically distinct from all other clinically available antibiotics and is isolated as a white crystalline solid.

INDICATIONS FOR SWINE:
LincoMed® 100 is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. This includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, Erysipelothrix and Mycoplasma spp.

It is also indicated for the treatment of mycoplasma pneumonia.

CONTRAINDICATIONS:
As with all drugs, use of LincoMed® 100 is contraindicated in animals previously found to be hypersensitive to the drug.

Residue Warning: Swine intended for human consumption should not be slaughtered within 48 hours of latest treatment.


CAUTION:
If no improvement is noted within 48 hours, consult a veterinarian.

ADVERSE REACTIONS:
The intramuscular administration to swine may cause a transient diarrhea or loose stools. Although this effect has rarely been reported, one must be alert to the possibility that it may occur. Should this occur, it is important that the necessary steps be taken to prevent the effects of dehydration.

DOSAGE AND ADMINISTRATION:
For arthritis or mycoplasma pneumonia - 5 mg per pound of body weight intramuscularly once daily for three to seven days as needed. One mL per 20 lb body weight will provide 5 mg/lb.

For optimal results, initiate treatment as soon as possible. As with any multi-dose vial, practice aseptic techniques in withdrawing each dose. Adequately clean and disinfect the vial closure prior to entry with a sterile needle and syringe. No vial closure should be entered more than 20 times.

Each mL contains:
Lincomycin hydrochloride equivalent to lincomycin 100 mg; also benzyl alcohol 9.45 mg added as a preservative.

HOW SUPPLIED:
LincoMed® is available in two concentrations: 100 mg/mL and 300 mg/mL.
100mg/mL: Supplied in 100 mL multiple dose vial.

300 mg/mL: For use in swine weighing 300 pounds or more. Supplied in 100 mL multiple dose vial.

STORE AT 20°C - 25°C (68°F - 77°F).

KEEP FROM FREEZING.
### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:61133-6000-1</td>
<td>100 mL in 1 VIAL, MULTI-DOSE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANADA</td>
<td>ANADA200368</td>
<td>08/02/2006</td>
<td></td>
</tr>
</tbody>
</table>

Labeler - Bimeda, Inc. (060492923)

Registrant - Bimeda, Inc. (060492923)

### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bimeda-MTC Animal Health</td>
<td></td>
<td>256232216</td>
<td>manufacture</td>
</tr>
</tbody>
</table>

Revised: 11/2018
LincoMed® 300
lincomycin injection, USP
SWINE ANTIBIOTIC
Restricted Drug (California) - Use only as Directed.
For Use in Animals Only
ANADA 200-368, Approved by FDA
Net Content: 100 mL (3.3 fl oz)
For use in swine weighing 300 pounds or more.
For Intramuscular Use in Swine Only
LincoMed® 300 contains lincomycin hydrochloride, an antibiotic produced by Streptomyces lincolnensis var. lincolnensis which is chemically distinct from all other clinically available antibiotics and is isolated as a white crystalline solid.

INDICATIONS FOR SWINE:
LincoMed® 300 is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. This includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, Erysipelothrix and Mycoplasma spp.
It is also indicated for the treatment of mycoplasma pneumonia.

CONTRAINDICATIONS:
As with all drugs, the use of LincoMed® 300 is contraindicated in animals previously found to be hypersensitive to the drug.

Residue Warning: Swine intended for human consumption should not be slaughtered within 48 hours of latest treatment.


CAUTION:
If no improvement is noted within 48 hours, consult a veterinarian.

ADVERSE REACTIONS:
The intramuscular administration to swine may cause a transient diarrhea or loose stools. Although this effect has rarely been reported, one must be alert to the possibility that it may occur.
Should this occur, it is important that the necessary steps be taken to prevent the effects of dehydration.

DOSAGE AND ADMINISTRATION:
For arthritis or mycoplasma pneumonia - 5 mg/lb body weight intramuscularly once daily for three to seven days as needed. One mL per 60 lb body weight will provide 5 mg/lb.
For optimal results, initiate treatment as soon as possible. As with any multi-dose vial, practice aseptic techniques in withdrawing each dose. Adequately clean and disinfect the vial closure prior to entry with a sterile needle and syringe. No vial closure should be entered more than 20 times.

Each mL contains:
Lincomycin hydrochloride equivalent to lincomycin 300mg; also benzyl alcohol 9.45 mg added as a
preservative.

**HOW SUPPLIED:**

LincoMed® is available in two concentrations: 100 mg/mL and 300 mg/mL.

100 mg/mL: Supplied in 100 mL multiple dose vial.

300 mg/mL: For use in swine weighing 300 pounds or more. Supplied in 100 mL multiple dose vial.

**STORAGE:** Store at 20°C - 25°C (68°F - 77°F).

**KEEP FROM FREEZING**

---

**LINCOMED 300**

*lincomycin injection*

### Product Information

- **Product Type:** OTC ANIMAL DRUG
- **Route of Administration:** INTRAMUSCULAR
- **Item Code (Source):** NDC:61133-6001

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lincomycin (UNII: BOD072YW0F) (Lincomycin - UNII:BOD072YW0F)</td>
<td>Lincomycin</td>
<td>300 mg in 1 mL</td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:61133-6001-1</td>
<td>100 mL in 1 VIAL, MULTI-DOSE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANADA</td>
<td>ANADA200368</td>
<td>08/02/2006</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Bimeda, Inc. (060492923)

**Registrant** - Bimeda, Inc. (060492923)

### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bimeda-MTC</td>
<td></td>
<td>256232216</td>
<td>manufacture</td>
</tr>
</tbody>
</table>

### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jiangxi Guo Yao Pharmaceutical</td>
<td></td>
<td>420560294</td>
<td>api manufacture</td>
</tr>
</tbody>
</table>

Revised: 12/2018